John Houston - Arvinas President CEO, Director
| ARVN Stock | USD 33.45 0.01 0.03% |
CEO
Dr. John Houston Ph.D. is President, Chief Executive Officer, Director of the company. He has served as a member of our board of directors and as our President and Chief Executive Officer since September 2017. Dr. Houston served as our President of Research and Development and Chief Scientific Officer from January 2017 to September 2017 and has functioned as our principal executive officer since February 2017. Prior to joining Arvinas, Dr. Houston served as Senior Vice President of Specialty Discovery and RD Site Evolution at Bristol Myers Squibb Company, a biopharmaceutical company, from September 2015 to August 2016, and as Senior Vice President Disease Sciences and Biologics from October 2010 to September 2015 since 2017.
| Age | 64 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 5 Science Park, New Haven, CT, United States, 06511 |
| Phone | 203 535 1456 |
| Web | https://www.arvinas.com |
Arvinas Management Efficiency
The company has return on total asset (ROA) of (0.195) % which means that it has lost $0.195 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5997) %, meaning that it created substantial loss on money invested by shareholders. Arvinas' management efficiency ratios could be used to measure how well Arvinas manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to drop to -0.4. At this time, Arvinas' Non Currrent Assets Other are very stable compared to the past year. As of the 18th of April 2024, Other Current Assets is likely to grow to about 8.4 M, while Total Assets are likely to drop about 753.2 M.Similar Executives
| Found 2 records | CEO Age | ||
| Joseph Reilly | Provident Bancorp | 66 | |
| David Mansfield | Provident Bancorp | 62 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.19 |
Arvinas Leadership Team
Elected by the shareholders, the Arvinas' board of directors comprises two types of representatives: Arvinas inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arvinas. The board's role is to monitor Arvinas' management team and ensure that shareholders' interests are well served. Arvinas' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arvinas' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Santos, CFO, Vice President - Business Development | ||
| Leslie Norwalk, Director | ||
| John Grosso, Senior Operations | ||
| Randy Teel, Senior Development | ||
| John Houston, President CEO, Director | ||
| Edward Kennedy, Independent Director | ||
| Jakob Loven, Independent Director | ||
| Ronald MD, Chief Officer | ||
| Steve Weiss, Senior Officer | ||
| Oto Cavalcante, Chairman of the Board | ||
| Ronald Peck, Chief Medical Officer | ||
| Bradley Margus, Independent Director | ||
| Angela Cacace, Senior Biology | ||
| Sean Cassidy, CFO | ||
| Jared JD, General Secretary | ||
| Timothy Shannon, Independent Chairman of the Board | ||
| Briggs Morrison, Independent Director | ||
| David MBA, Principal VP | ||
| Andrew Crew, CTO | ||
| Alberto Menache, Independent Director | ||
| CPA CPA, CFO Treasurer | ||
| Ian Taylor, Chief Scientific Officer | ||
| Liam Ratcliffe, Independent Director | ||
| Matthew JD, Gen Sec | ||
| Martin Escobari, Independent Director | ||
| Lisa Sinclair, Senior Operations | ||
| John Northcott, Chief Officer | ||
| Ari Neto, CEO, Director | ||
| Joao Silva, COO | ||
| Kush Parmar, Independent Director | ||
| Jeff Boyle, Vice Relations |
Arvinas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arvinas a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | 3.84 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 68.08 M | ||||
| Shares Owned By Insiders | 2.50 % | ||||
| Shares Owned By Institutions | 97.27 % | ||||
| Number Of Shares Shorted | 8.6 M | ||||
| Price To Earning | (0.45) X | ||||
| Price To Book | 3.74 X |
Pair Trading with Arvinas
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arvinas position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arvinas will appreciate offsetting losses from the drop in the long position's value.Moving against Arvinas Stock
| 0.61 | DOMH | Dominari Holdings | PairCorr |
| 0.59 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.56 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.55 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.54 | VIRI | Virios Therapeutics Llc Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Arvinas could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arvinas when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arvinas - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arvinas to buy it.
The correlation of Arvinas is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arvinas moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arvinas moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arvinas can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arvinas. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Arvinas Stock analysis
When running Arvinas' price analysis, check to measure Arvinas' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arvinas is operating at the current time. Most of Arvinas' value examination focuses on studying past and present price action to predict the probability of Arvinas' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arvinas' price. Additionally, you may evaluate how the addition of Arvinas to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Arvinas' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.62) | Revenue Per Share 1.414 | Quarterly Revenue Growth 0.042 | Return On Assets (0.20) | Return On Equity (0.60) |
The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.